德克萨米他治疗方案和儿童喘恶化的临床结果

相关实验视频

Updated: Jan 24, 2026

11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K

Shivam Dave¹, Israel Green-Hopkins², Naomi S Bardach³

¹Department of Department of Pediatrics, University of California, San Francisco, San Francisco, CA.

Annals of emergency medicine

|January 23, 2026

概括

将近三分之二的患有喘恶化症的儿童服用了两剂德克萨,但这并没有改善结果. 一剂德克萨米他可能足以治疗儿童喘恶化.

科学领域:

儿科急救医学儿科急救医学
药理学药理学是指药理学的学科.
呼吸系统医学呼吸系统医学

背景情况:

德克萨米他是一种常见的治疗儿童喘恶化.
对于从急诊室 (ED) 出院的儿童来说,甲剂量的最佳数量尚未确立.
目前的做法有所不同,许多儿童接受两剂疫苗.

研究的目的:

为了检查儿科喘恶化时德克萨米他剂量变化的变化.
为了确定一剂或两剂德甲是否会影响从ED出院的儿童的临床结果.
为了测试假设,结果在一剂和两剂之间没有差异.

主要方法:

对2063名儿童 (2-20岁) 的回顾性队列研究,在两个ED中治疗喘恶化.
主要暴露:处方一个或两个剂量德克萨梅他在放出.
主要结局:ED在14天内重访;次要结局:在14天内住院.
倾向性得分调整与治疗权重的逆概率被用来控制混.

主要成果:

61.9%的儿童接受了两剂德甲.
在加权队列中,ED复诊率相似:一次剂量为5.2%,两次剂量为5.7% (风险差异:0.45%).
住院率也是相似的:0.85%用于一剂 vs.0.83%用于两剂 (风险差异:0.02%).

结论:

大多数患有喘恶化症的儿童被处方了两剂德克萨.
在一剂和两剂之间,没有观察到ED复诊或住院的显著差异.
研究结果表明,对于许多患有喘恶化并从ED出院的儿童来说,单剂量德克萨梅他可能足够.

关键词:

喘喘是一种德克萨米他是一种基于证据的医学是基于证据的医学.最佳的剂量是最佳的剂量.

相关概念视频

01:29

Asthma-I: Introduction

3.4K

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...

3.4K

01:26

Asthma-II: Pathophysiology and Classification

4.2K

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

4.2K

01:20

Asthma: Pathogenesis and Management

1.3K

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

1.3K

01:24

Asthma-III: Symptoms and Complications

3.3K

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma

3.3K

01:30

Asthma-IV: Diagnostic and Management

3.1K

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

3.1K

01:15

Drug Dosage Regimen: Overview

4.4K

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...